Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART19 in R/R CD19+ Leukemia and Lymphoma
NCT02374333Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2014
- Primary completion
- Sep 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huCART-19 in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), sponsored by University of Pennsylvania. Primary endpoint: Occurrence of study related adverse events at 24 weeks. Started Mar 2014; status: completed.
02
Drugs
huCART-19
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02374333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374333.